Congratulations to alum Lauren Swidler on her new position with Sanofi. Since 2018, Lauren has been a valued colleague and member of Choate Government Enforcement & Compliance team. We wish you well Lauren!
Partner Restructuring and Insolvency at Womble Bond Dickinson
Looking forward to this and being back in Dublin. If you are free to catch up with the WBD team of myself, Amy Gallimore, Peter Maxwell, Fintan Wolohan Jeffrey Tarkenton or Wojciech F. Jung, Esq. it will be great to see you.
Nursing, Pharmacist, Clinical Governance Conference. The film of all conference presentations is available for free to all on our website. The 2024 conference details will soon be released.
#hazardousdrugs “All drugs are toxic at some level, of course. “When we talk about hazardous drugs, we are referring to agents that have some identifiable, established toxicity at a lower dose, typically carcinogenicity or teratogenicity or other developmental toxicities,” Dr. Ganio said. “When NIOSH evaluates a drug for inclusion on their list, they will look at the primary literature as well as sources like DrugBank, DailyMed, the packaging and labeling, and any safety data sheets that exist.”
When NIOSH experts make these determinations, “they are looking at the molecule itself, and [whether there] is some sort of hazard [posed],” Dr. Ganio stressed. “They’re not looking at how [the medications] are used in the healthcare setting—that’s our job as stewards of occupational safety.” #occupationalhealth#healthandsafety#pharmacovigilance#cancer#nursing#oncology#pharmacy#SACT#chemotherapy
Patient and Healthcare Professional Safety Advocate
"That’s where the distinction between NIOSH’s role in this and [a pharmacy’s] role under USP Chapter <800> comes in. They’re identifying that a hazard is there. It’s up to us in our own settings to control exposure and risk.”
What a way to start the week! Presenting about Centrus and "Enhancing Translational Safety Assessment" first thing!
To find out more about the webinar, or about Centrus, DM me.
#translationalscience#safetyassessment#womeninstem
Scientific Application Director - In Silico & Translational Science Solutions at Instem
Another early start for Brenda Finney and me this morning! 🌄 ☕ 💻
Together with Takayuki Anzai, we participated in the Korea New Drug Research Association Online Event in partnership with Ginapath!
For the online event we presented "Enhancing Transitional Safety Assessment" and "Target Safety Assessment for early discovery and/or early phase of New Drug Development."
To find out more information about the webinar, please DM me 📲
Join me for an insightful panel discussion at the BIO International Convention in San Diego on June 5. Our session, "Evolution of the IRA: A New-Year, a Potential New Administration, Yet Tackling the Same Access and Affordability Challenges," will feature expert panelists like William Roth, Gerry Gleeson, Albert Thigpen, and William Sarraille. They will demystify how IRA will change the landscape for emerging pharmaceutical companies and put recent developments in plain language. Don't miss out on this opportunity to stay ahead of the curve in the ever-changing world of drug pricing and Medicare negotiation. #BIO2024#IRA#drugpricing#medicarenegotiation
Human Advocate for Equity in Access and Informed Decision Making | Integrity, Ethics, Inclusion and Transparency by Design | Enabling Co-Creation for a Healthier Future for all | Global R&D Collaborations | Convergence
Driving meaningful innovative change across research & development to ensure a better understanding and predictability of safety events! A long term dream of mine. Enabling Translational Safety through collaboration. Co-Leading sustainability efforts across the ecosystem to enable high quatity product lifecycle management, efficiency and acceleration of medicines developmets.
Teaming up! Our Enabling Translational Safety team’s first in-person workshop at Pfizer in Groton, CT, was nothing short of a success. Nearly 30 participants from 11 member companies participated in a productive day of focused sessions, cross-functional interactive groups, and dedicated team working time. The workshop strengthened project alignment and fostered a strong sense of community: key ingredients for future progress.
Wonderful video on career path and development that would recommend watching! Key nugget is don't obsess about your career path or where you you think you should end up; instead obsess about doing the best job with thrusting all of YOU into the role/job you have now and it's that complete lean-in which will unlock what is next for you in your career! Have a think and watch below!
“Worry less about having a strategy for your career and worry a lot about loving the job you are in and being the best at it... that's how you unlock opportunity.”
GSK CEO and Microsoft board member Emma Walmsley never had a master plan for where her career path would take her.
In the latest episode of The Path, Emma tells me how she let curiosity and a sense of adventure guide her from multiple roles in one the world’s biggest cosmetics companies to taking on the leadership of a pharmaceutical giant.
Find out more about Emma’s remarkable career journey below and never miss an episode of The Path by subscribing at https://lnkd.in/dr8AChyD
I help leaders build future-readiness for themselves and their teams.
I lead Unqbe, a Think-tank and Consulting Firm Focused on the Future of Work, and Leadership. I also write a popular newsletter and host a podcast.
I love the idea that Emma speaks about how a love for Latin and language helped her... understand 'people'. And that has helped her across her career as a leader.
One can succeed in so many different ways. And finding work that you love really allows you to operate from a place of strength. And that is so wonderful.
So many of us, may not have 'master-plans'. Particularly 'master-plans' that are strategic. In fact the future is changing so fast, that having a master-plan will become less and less relevant.
What will be relevant? Excellence and learning.
Excellence unlocks new opportunities. And its hard to have excellence unless we can find ways to enjoy what we do.
Hence, the start... discovering what really drives you.
And then giving it your all.
“Worry less about having a strategy for your career and worry a lot about loving the job you are in and being the best at it... that's how you unlock opportunity.”
GSK CEO and Microsoft board member Emma Walmsley never had a master plan for where her career path would take her.
In the latest episode of The Path, Emma tells me how she let curiosity and a sense of adventure guide her from multiple roles in one the world’s biggest cosmetics companies to taking on the leadership of a pharmaceutical giant.
Find out more about Emma’s remarkable career journey below and never miss an episode of The Path by subscribing at https://lnkd.in/dr8AChyD
I am so happy for both you and Sanofi! I know you will be such an asset to them.